Lung cancer is the most common malignancy in many parts of the world. It is often diagnosed late and has one of the poorest outcomes among other cancers. Recent studies (NELSON from Europe and NLST from USA) have shown that lung cancer screening via computed tomography scans can identify lung cancer at an earlier stage in certain populations, and reduce mortality. The diagnosis and management of these tumors, with many being small nodules or ground glass changes, remain a challenge. The landscape and management of lung cancer in general have also changed dramatically in the last decade, perhaps more than any other thoracic disease. Advances in surgery and cancer genetics facilitate personalized drug therapies that can provide ever more complex and innovative treatment algorithms to fight this terrible disease. The role of liquid biopsies, more targeted bespoke drug therapies, non-invasive endoscopic treatments, and high-precision surgeries are only some of the evolving horizons in lung cancer management.

November 2022 is designated as "World Lung Cancer Awareness Month", with various global activities that highlight and increase awareness of lung cancer for research support and development. We would like to share some of the high-quality and innovative research findings published in Cancers (ISSN: 2072-6694).

The list of relevant papers can be seen below:

“The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells”
by Dong Young Kang, Nipin Sp, Eun Seong Jo, Alexis Rugamba, Dae Young Hong, Hong Ghi Lee, Ji-Seung Yoo, Qing Liu, Kyoung-Jin Jang and Young Mok Yang
Available online: https://www.mdpi.com/2072-6694/12/3/727

“Extracellular Vesicle lincRNA-p21 Expression in Tumor-Draining Pulmonary Vein Defines Prognosis in NSCLC and Modulates Endothelial Cell Behavior”
by Joan J. Castellano, Ramon M. Marrades, Laureano Molins, Nuria Viñolas, Jorge Moises, Jordi Canals, Bing Han, Yan Li, Daniel Martinez, Mariano Monzó et al.
Available online: https://www.mdpi.com/2072-6694/12/3/734

“Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient”
by Giovanni Rossi, Alessandro Russo, Marco Tagliamento, Alessandro Tuzi, Olga Nigro, Giacomo Vallome, Claudio Sini, Massimiliano Grassi, Maria Giovanna Dal Bello, Simona Coco et al.
Available online: https://www.mdpi.com/2072-6694/12/5/1125

“¹⁸F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival”
by Giulia Polverari, Francesco Ceci, Valentina Bertaglia, Maria Lucia Reale, Osvaldo Rampado, Elena Gallio, Roberto Passera, Virginia Liberini, Paola Scapoli, Vincenzo Arena et al.
Available online: https://www.mdpi.com/2072-6694/12/5/1163

“Association of a CT-Based Clinical and Radiomics Score of Non-Small Cell Lung Cancer (NSCLC) with Lymph Node Status and Overall Survival”
by Francesca Botta, Sara Raimondi, Lisa Rinaldi, Federica Bellerba, Federica Corso, Vincenzo Bagnardi, Daniela Origgi, Rocco Minelli, Giovanna Pitoni, Francesco Petrella et al.
Available online: https://www.mdpi.com/2072-6694/12/6/1432

“Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab”
by Romain-David Seban, Jean-Baptiste Assié, Etienne Giroux-Leprieur, Marie-Ange Massiani, Michael Soussan, Gérald Bonardel, Christos Chouaid, Margot Playe, Lucas Goldfarb, Boris Duchemann et al.
Available online: https://www.mdpi.com/2072-6694/12/8/2234

“Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study”
by Pierre-Jean Lamy, Paul van der Leest, Nicolas Lozano, Catherine Becht, Frédérique Duboeuf, Harry J. M. Groen, Werner Hilgers, Nicolas Pourel, Naomi Rifaela, Ed Schuuring et al.
Available online: https://www.mdpi.com/2072-6694/12/10/3002

“Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies”
by Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow and Giandomenico Roviello
Available online: https://www.mdpi.com/2072-6694/12/11/3293

“A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC”
by Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson and Bilal Piperdi
Available online: https://www.mdpi.com/2072-6694/12/12/3648

“Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review”
by Alice Indini, Erika Rijavec and Francesco Grossi
Available online: https://www.mdpi.com/2072-6694/13/8/1794

You are welcome to submit relevant papers to the Special Issue “World Lung Cancer Awareness Month”.

Dr. Calvin Sze Hang Ng
Editorial Board Member of Cancers